- Home
- COLL vs PDX Comparison
COLL vs PDX Comparison
Compare COLL & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- PDX
- Stock Information
- Founded
- COLL 2002
- PDX 2019
- Country
- COLL United States
- PDX NY
- Employees
- COLL N/A
- PDX N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- PDX Finance/Investors Services
- Sector
- COLL Health Care
- PDX Finance
- Exchange
- COLL Nasdaq
- PDX Nasdaq
- Market Cap
- COLL 1.1B
- PDX 1.2B
- IPO Year
- COLL 2015
- PDX N/A
- Fundamental
- Price
- COLL $33.35
- PDX $32.01
- Analyst Decision
- COLL Strong Buy
- PDX
- Analyst Count
- COLL 5
- PDX 0
- Target Price
- COLL $43.80
- PDX N/A
- AVG Volume (30 Days)
- COLL 486.5K
- PDX N/A
- Earning Date
- COLL 02-20-2025
- PDX 01-01-0001
- Dividend Yield
- COLL N/A
- PDX 4.95%
- EPS Growth
- COLL 757.11
- PDX N/A
- EPS
- COLL 2.16
- PDX N/A
- Revenue
- COLL $599,245,000.00
- PDX N/A
- Revenue This Year
- COLL $13.20
- PDX N/A
- Revenue Next Year
- COLL $17.63
- PDX N/A
- P/E Ratio
- COLL $15.42
- PDX N/A
- Revenue Growth
- COLL 9.62
- PDX N/A
- 52 Week Low
- COLL $28.39
- PDX $13.52
- 52 Week High
- COLL $42.29
- PDX $21.05
- Technical
- Relative Strength Index (RSI)
- COLL 62.31
- PDX 74.76
- Support Level
- COLL $32.29
- PDX $25.74
- Resistance Level
- COLL $33.99
- PDX $32.65
- Average True Range (ATR)
- COLL 1.29
- PDX 0.98
- MACD
- COLL 0.51
- PDX 0.64
- Stochastic Oscillator
- COLL 87.40
- PDX 90.75
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited term, closed-end management investment company registered under the Investment Company. The fund's primary investment objective is to seek current income as a primary objective and capital appreciation as a secondary objective.